Silihan lan utang jangka dawa perusahaan CeriBell Corp (CBLL)

The stock chart for CeriBell, Inc. (CBLL), a neurotechnology specialist, shows long-term debt at 0.02. Unique patents for AI diagnostics and strict FDA oversight provide a moat for the business. Operational stability is supported by the neutral status of biomedicine in global politics. Further growth relies on the implementation of systems in intensive care units and the receipt of insurance reimbursements for examinations.

This metric is calculated by aggregating all liabilities with a maturity of more than one year. This indicator determines financial leverage and the business's ability to service capital expenditures without the risk of default. For CeriBell, Inc. (CBLL), such funds are critical when scaling the production of AI-powered neurodiagnostic systems. By analyzing the company's long-term debt structure, an investor assesses the sustainability of its innovation expansion in neurology.